Talk Bio

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations

Ironwood Pharmaceuticals' Stock Plummets Following Layoffs and FDA Setback for Apraglutide